Nurix Therapeutics Inc. (NRIX)
NASDAQ: NRIX
· Real-Time Price · USD
11.20
-0.33 (-2.86%)
At close: May 01, 2025, 3:57 PM
11.16
-0.36%
After-hours: May 01, 2025, 04:01 PM EDT
-2.86% (1D)
| Bid | 11.13 |
| Market Cap | 853.84M |
| Revenue (ttm) | 56.42M |
| Net Income (ttm) | -208.4M |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -4.01 |
| Forward PE | -3.41 |
| Analyst | Buy |
| Ask | 11.2 |
| Volume | 525,798 |
| Avg. Volume (20D) | 982,996 |
| Open | 11.41 |
| Previous Close | 11.53 |
| Day's Range | 11.13 - 11.52 |
| 52-Week Range | 8.18 - 29.56 |
| Beta | 2.24 |
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 286
Stock Exchange NASDAQ
Ticker Symbol NRIX
Website https://www.nurixtx.com
Analyst Forecast
According to 17 analyst ratings, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 176.79% from the latest price.
Stock Forecasts4 months ago
+6.78%
Nurix Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
+6.53%
Nurix Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a price target of $35.
